Evolus, Inc. (NASDAQ:EOLS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Evolus, Inc. (NASDAQ:EOLS) have received a consensus rating of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $16.00.

EOLS has been the subject of several research analyst reports. BTIG Research reissued a “buy” rating and issued a $13.00 price objective on shares of Evolus in a research note on Wednesday, March 4th. Weiss Ratings downgraded Evolus from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. Finally, Wall Street Zen downgraded Evolus from a “buy” rating to a “hold” rating in a research note on Sunday, March 15th.

Insider Activity

In related news, insider Rui Avelar sold 29,996 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total value of $146,680.44. Following the completion of the sale, the insider directly owned 430,542 shares of the company’s stock, valued at approximately $2,105,350.38. This represents a 6.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Moatazedi sold 13,669 shares of the stock in a transaction dated Friday, March 20th. The stock was sold at an average price of $4.75, for a total value of $64,927.75. Following the completion of the sale, the insider directly owned 604,700 shares of the company’s stock, valued at approximately $2,872,325. This represents a 2.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 163,504 shares of company stock valued at $797,184. Company insiders own 5.00% of the company’s stock.

Institutional Investors Weigh In On Evolus

Hedge funds have recently bought and sold shares of the business. Nantahala Capital Management LLC raised its stake in shares of Evolus by 1.6% during the 4th quarter. Nantahala Capital Management LLC now owns 5,820,649 shares of the company’s stock worth $38,707,000 after purchasing an additional 93,792 shares in the last quarter. Caligan Partners LP raised its stake in shares of Evolus by 23.8% during the 3rd quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock worth $25,413,000 after purchasing an additional 796,973 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Evolus by 3.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,428,943 shares of the company’s stock worth $21,054,000 after purchasing an additional 110,693 shares in the last quarter. Braidwell LP purchased a new stake in shares of Evolus during the 4th quarter worth about $20,650,000. Finally, Soleus Capital Management L.P. raised its stake in shares of Evolus by 96.4% during the 2nd quarter. Soleus Capital Management L.P. now owns 2,119,000 shares of the company’s stock worth $19,516,000 after purchasing an additional 1,039,842 shares in the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.

Evolus Stock Up 0.3%

NASDAQ:EOLS opened at $6.70 on Wednesday. Evolus has a 1-year low of $3.86 and a 1-year high of $10.62. The firm has a market capitalization of $441.26 million, a price-to-earnings ratio of -10.00 and a beta of 1.34. The stock has a fifty day simple moving average of $5.56 and a 200 day simple moving average of $5.56.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Monday, May 4th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The company had revenue of $73.14 million during the quarter, compared to analyst estimates of $72.52 million. During the same period last year, the business earned ($0.30) EPS. Equities analysts predict that Evolus will post -0.38 earnings per share for the current year.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.